Advertisement

Topics

Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

04:06 EST 14 Nov 2017 | Yahoo News

A unit of healthcare conglomerate Johnson & Johnson has dropped a lawsuit it filed to block a copy of its rheumatoid arthritis drug Remicade produced by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. Janssen Biotech Inc, in a document to the U.S. District Court of New Jersey dated Friday and seen by Reuters, voluntarily dismissed its suit to block Samsung Bioepis' biosimilar of Remicade from sale. Remicade is Johnson & Johnson's biggest selling drug, with U.S. sales of about $5 billion a year.


Original Article: Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

NEXT ARTICLE

More From BioPortfolio on "Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...